bioAffinity Technologies Stock Draws Fresh Attention From Traders
bioAffinity Technologies shares rose to $1.69 after the company filed a notice on physician education for its CyPath Lung cancer test. The Society for Advanced Bronchoscopy will host a June 16 webinar on the test’s use in lung cancer detection. CyPath Lung unit sales in April jumped nearly 300% from a year earlier, according to preliminary figures. The company faces competition from Biodesix and Veracyte in lung nodule diagnostics.